WASHINGTON — The Supreme Court will next week consider a case that has the potential to upend how drug companies can defend themselves from patient lawsuits.

The case, Merck Sharp & Dohme Corp. v. Doris Albrecht, began as a collection of lawsuits by more than a thousand patients who used the osteoporosis drug Fosamax. The patients say the drug maker failed to adequately warn them that taking the drug might make them more likely to fracture their femurs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • this seems pretty black and white. Merck cannot communicate anything off-label about their drugs. They asked FDA to update their label. FDA determined there was insufficient evidence to make that update, and it appears any update related to bone fractures.
    I suspect if the lower court had ruled MSD wasn’t liable, the SCOTUS would not have taken this case. They took it to straighten out a clear wrong decision.
    I feel terrible for the suffering, including I assume disability, that some patients taking Fosamax have experienced. And FDA should probably have acted differently. If anyone is at blame here it’s them. But there’s no $$ in suing FDA, is there?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy